Stockreport

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

XTL Biopharmaceuticals Ltd. - American Depositary Shares  (XTLB) 
US:NASDAQ Investor Relations: xtlbio.com
PDF Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now aff [Read more]